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Abstract 
The few existing long-term, neuropsychological follow-up studies of early-onset schizophrenia 
(EOS) patients have reported relative stability in some cognitive functions but abnormal 
developmental trajectories in verbal memory, set shifting, aspects of attention, and speed of 
information processing throughout late adolescence into early adulthood. The current 5-year follow-
up study compared the development of specific cognitive functions in EOS patients (N=17) from 
the time of first-episode to chronic phase with that of healthy controls (N=38) and secondarily to 
patients with other early-onset, non-organic, non-affective psychoses (EOP) (N=11). Speed of 
processing of executive functions, set shifting, and attention improved significantly in the healthy 
controls and reflected continuous functional maturation during late adolescence and early 
adulthood. The developmental progression of attention and set shifting but not speed of processing 
of executive functions was significantly subnormal in EOS patients. Other specific cognitive 
functions that had attained functional maturity in the healthy controls around the time of the 
baseline assessment showed normal development in EOS patients during the follow-up period, 
indicating stable cognitive deficits. These results suggest post-onset developmental deficits in two 
out of the three aspects of attention and executive functions that have protracted maturational 
trajectories and that overlap the age of onset of EOS. No significant difference in the development 
of any specific cognitive function was found between the EOS and EOP group. 
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Introduction 
It has been estimated that approximately 4 % of all schizophrenia patients have their illness onset 
before 18 years of age [14], which is termed early-onset schizophrenia (EOS) [84]. Childhood-onset 
of schizophrenia (COS, onset by age 12) [39] is extremely rare [12;80], whereas the incidence 
increases between the ages 13 to 17 years [70;80]. A study including COS, also termed very early-
onset schizophrenia [39], observed cognitive deficits of comparable severity to those of patients 
with onset of schizophrenia between the ages of 13 and 18 years [71], and consequently, no 
distinction is made between COS and EOS patients in this paper. Previous controlled studies of 
EOS patients and adolescent patients with schizophrenia spectrum disorders have reported 
significant deficits in several specific cognitive functions such as speed of processing, attention, 
verbal memory, aspects of executive functions including mental flexibility and working memory, 
etc. [6;22;29;36;44-46;63;71;81;85]. Significant intelligence impairments have also been found in 
these clinical groups [22;29;36;46;63;71;81;81;85]. A few of these studies included patients with 
illness onset at the age of 18 years.  
Only very few prospective longitudinal studies have assessed a possible change in the severity of 
intelligence impairments and specific cognitive deficits over time in EOS. A decline in intelligence, 
as reflected in deterioration in age-adjusted full scale intelligence quotient (FSIQ), has been 
observed around the time of illness onset in COS patients [27]. Similarly, post-onset IQs 
deteriorated relative to premorbid levels in a study of EOS patients with premorbid mental 
retardation (MR) [49]. Long-term stability in FSIQ has been observed in EOS patients [24;27]. 
However, a significant decline in FSIQ has been reported over a shorter time interval in COS 
patients [9]. Administering the same version of a Wechsler intelligence test and using the same 
baseline norms at baseline and after 5 years, our group previously found that FSIQ improvement 
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was significantly smaller in EOS patients than in healthy controls, which suggested an abnormally 
slow acquisition of new intellectual information and skills during the first years after full clinical 
presentation [41]. In continuation of these results on intelligence development, the focus of our 
current study is on the development of specific cognitive functions in EOS. Frangou et al. (2008) 
reported a significant deterioration in immediate verbal memory and attention during the late 
adolescent years in EOS patients, while the performance in healthy controls improved. No 
differential change in the planning aspect of executive functions (EF) was observed, whereas 
information processing speed improved in EOS but not in controls [24]. In an impressive 13 year 
follow-up study, a significant decline in verbal memory and a lack of improvement in speed of 
information processing and the set shifting aspect of EF have also been found in EOS patients as 
opposed to stability and improvement among healthy controls [64]. Finally, a significant 
deterioration in executive attention has been found in EOS patients, while the performance in 
healthy controls remained stable [62].  
 
EF are mental control processes that for example enable self-control necessary for the attainment of 
a future goal [20]. Contemporary theory suggest there are no unitary EF [26;78] but separable and 
related subprocesses [57]. Several definitions of EF and possible subprocesses exist [42]. The 
primary objective of the current study was to assess the development of different aspects of EF (set 
shifting, planning, working memory, speed of processing of EF) and other specific cognitive 
functions (attention, reaction time, motor speed, verbal memory) in first-episode EOS patients.  
 
The development in EOS patients from the time of their first episode to 5 years post onset was 
primarily compared with that of healthy controls. We hypothesized that verbal memory would 
deteriorate in EOS patients but not in healthy controls. In addition, we expected subnormal growth 
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in set shifting, reaction time, and attention in EOS patients. Finally, we hypothesized a relatively 
stable development in planning, working memory, speed of processing of EF, and motor speed in 
EOS patients.  
 
The development in EOS patients during the 5 year follow-up period was secondarily compared to 
that of patients who at baseline had been diagnosed with other non-organic, non-affective psychoses 
in order to evaluate the specificity of a possible abnormal cognitive development in EOS patients. 
Compared to schizophrenia, the psychotic disorders included in the group of other non-organic, 
non-affective psychoses at baseline (see Appendix A) are, according to the ICD-10 [86] criteria, 
characterized by fewer, less specific psychotic symptoms or of a relatively short duration. In 
addition, preliminary analyses found some specific cognitive deficits at baseline to be substantially 
but not significantly smaller in the group of other non-organic, non-affective psychotic disorders 
than in the EOS group (see Figure 2). Thus, we hypothesized that these disorders, as a group, might 
be associated with less abnormal cognitive development than EOS during the follow-up period.  
 
Methods 
Sample 
Forty eight patients, who met the ICD-10 [86] criteria for a first-episode, non-organic, psychotic 
disorder or schizotypal disorder, were recruited at baseline. Patients were between 10 and 17 years 
of age (both inclusive) at the time of their first contact with child- and adolescent psychiatric 
departments in the Copenhagen and Northern Zealand catchment areas in Denmark. The patient 
exclusion criteria were fulfilment of the ICD-10 diagnostic criteria for psychotic disorder due to 
psychoactive substance use (F1x.5), antipsychotic treatment for more than 6 months, the presence 
of any chronic somatic disease, severe head injury, neurological illness, compulsory hospitalization, 
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or a premorbid diagnosis of mental retardation [71;89]. Patients and their parents were informed 
about the follow-up study and gave informed consent to be contacted for a follow-up assessment.  
The present analyses includes comparisons between 17 EOS patients and 11 patients with other 
early-onset, non-organic, non-affective psychoses (EOP) as diagnosed at baseline. Appendix A 
presents the baseline diagnostic distributions of these subgroups. The patients diagnosed with 
affective psychoses and schizotypal disorder at baseline, were excluded. Three EOS patients were 
antipsychotic naïve at the baseline neuropsychological assessment while the remaining 14 patients 
(82 %) had been treated with various first and second generation antipsychotic medications with a 
mean treatment duration of 8.3 weeks (SD=6.1) (see Table 1). At baseline, 6 of the 11 patients with 
EOP (55 %) were treated with various first and second generation antipsychotic medications with a 
mean treatment duration of 6.2 weeks (SD=6.0); one EOP patient received additional 
anticholinergic treatment which may impair cognition [77]. As shown in Table 1, the EOS and the 
healthy control groups did not differ regarding mean age at baseline or follow-up, length of follow-
up interval, number of years of education, or gender distribution, but parental baseline income and 
education/occupation differed significantly between the two groups. No significant differences were 
observed between the EOS and EOP groups in educational and sociodemographic characteristics at 
baseline (see Table 1). In addition, no significant difference in age of onset of psychotic symptoms, 
duration of untreated psychosis, baseline psychoticism, disorganization, or negative symptom 
dimension severity was found between the EOS and EOP groups. Since the time of the first clinical 
presentation, patients in both clinical groups received standard treatment (which did not include 
cognitive training).  
Fifty three percent of EOS patients and 18 % of EOP patients reported being treated with 
antipsychotic medications at the time of the follow-up assessment (see Table 1). Two EOS patients 
received additional anticholinergic treatment at follow-up, but their cognitive performance did not 
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differ substantially from the remaining EOS patients and they were consequently included in all 
analyses.  
Two EOS patients were diagnosed with co-morbid mental retardation at baseline in spite of the fact 
that intelligence deficits had not been recognized at the time of inclusion in the study. Additionally, 
three EOS patients were diagnosed with co-morbid SUD at baseline, 2 of whom also had co-morbid 
SUD at follow-up. No EOP patients suffered SUD at baseline but 2 EOP patients were diagnosed 
with SUD at follow-up. 
Figure 1 here 
At baseline, 46 healthy controls were recruited from schools and institutions in Copenhagen and 
matched with the patients on gender and age (within 6 months). Exclusion criteria for control 
subjects were a history of psychiatric disorders, learning disability, mental retardation, chronic 
somatic or head injuries, neurological disease, abuse of psychoactive substances, or a psychotic 
disorder in any first-degree relatives. Figure 1 shows the retention and exclusion of patients and 
healthy controls from baseline through completion of the follow-up assessment. For a detailed 
description of the demographic characteristics of patients and controls, see Table 1. 
Table 1 here 
After complete written and oral description of the follow-up study, written informed consent was 
obtained from all subjects and from a parent, if the subject was younger than 18 years of age. The 
follow-up study was approved by the local Ethical Committees and carried out in accordance with 
the Helsinki declaration. The follow-up assessment was carried out on average 5.5 (SD=0.4) years 
after the baseline study. Patients and controls received a small financial incentive for their 
participation. 
 
Assessment of psychopathology 
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ICD-10 [86] diagnoses at baseline and follow-up were reached by consensus using the Schedules 
for Clinical Assessment in Neuropsychiatry Version 2.1 (SCAN 2.1) [87] based on video-monitored 
interviews and all available clinical information. Psychotic symptoms were assessed using the Scale 
for the Assessment of Positive Symptoms (SAPS) [4] and the Scale for the Assessment of Negative 
Symptoms (SANS) [3]. As shown in Table 1, psychotic symptoms were categorized into the 
psychoticism, disorganization, and negative symptom dimensions [5]. The age of onset of fully 
developed psychotic symptoms was assessed at baseline based on information derived from 
different sources inclusive the Interview for the Retrospective Assessment of the Onset of 
Schizophrenia (IRAOS) [30;52] administered to patients and parents at baseline. Based on 
information from IRAOS, the duration of untreated psychosis (DUP) [48] was calculated as the 
time interval between the onset of psychotic symptoms and the initiation of treatment, as indicated 
by the first appointment to the psychiatric department for psychotic symptoms. Similar to the 
baseline assessment, control subjects were interviewed using SCAN 2.1 again at follow-up to rule 
out the onset of a psychiatric disorder during the follow-up period.  
 
Assessment of socioeconomic status 
Parental education and occupation at baseline were rated into 6 social classes according to 
previously described criteria [31] and categorized into 3 groups (see Table 1). The parental 
household income at baseline was rated into one of three economic status groups (Low, Middle, or 
High). 
 
Cognitive assessment 
The cognitive deficits at baseline were assessed with a comprehensive neuropsychological test 
battery that included measures of different aspects of EF (Intra-Extra Dimensional Set Shift (IED) 
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[21;25], Stocking of Cambridge (SOC) [65], Wisconsin Card Sorting Test [55] (perseverative errors 
according to Nelson’s criteria [50]), Verbal Fluency tasks (category and letter) [50], Non-verbal 
Fluency Five-Point Test [68], and Trail Making Test A and B [50]. In addition, verbal memory was 
assessed with Buschke’s Selective Reminding Task [13], attention with Rapid Visual Information 
Processing (RVP) (version with one target sequence of three stimuli) [18], reaction time and 
movement latencies with Reaction Time (RTI) [75;76], spatial short-term memory with Spatial 
Span (SSP) [65], and spatial working memory with Spatial Working Memory (SWM) [65]. The 
same version of all the neurocognitive tasks was used at the baseline and follow-up assessments.  
In order to reduce the number of statistical comparisons and avoid redundancy, selected core test 
outcome measures were combined into composite cognitive domains according to their putative 
content, combining test scores reflecting the same functional domain [47]. The construction of the 
cognitive domains was based upon a model of the executive functions as separable and different 
functions and on the cognitive domains reported in the literature on cognitive deficits in EOS and 
adult onset schizophrenia (AOS) patients, e.g. [60]. We created six composite domains: Reaction 
time, Motor speed, Speed of processing of EF, Set shifting, Planning, and Working memory. In 
addition, an Attention and a Verbal memory domain were created, each comprising a single test 
outcome measure. The cognitive domains and their test components are presented in detail in Figure 
2.  
Except one alteration, the neuropsychological tests were administered in the same fixed order at 
follow-up as at the baseline assessment. Based on JRJ’s clinical assessment and the self-report of 
participants regarding recent use of alcohol and psychoactive substances on selected SCAN 2.1 
items [87] at the beginning of every test session, no patient or control subject was considered 
intoxicated during the neuropsychological follow-up assessments. At baseline, the 
neuropsychological test battery was administered by BF whereas at follow-up it was administered 
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by JRJ, who was blind with regard to the neuropsychological test scores at baseline. Patients and 
controls with incomplete cognitive data at baseline or follow-up were included in the statistical 
analyses and thus, the sample size varies. Apart from the SSP and SWM tests that were included in 
the battery somewhat late in the baseline assessment process, 12 of the EOS patients that 
participated at follow-up (71 %) had completed all tests at baseline, 3 patients missed one test score, 
and 2 patients missed two or more test scores. At follow-up, 15 EOS patients (88 %) had complete 
datasets, while 1 missed one test score, and 1 missed all computerized test scores due to computer 
problems. There were no missing data among controls.  
 
Data analyses  
Domain scores 
When appropriate, baseline and their equivalent follow-up test raw scores (i.e. not age normed) 
were logarithmically transformed to approximate a normal distribution. To accurately assess the 
stability of cognitive functioning over time, baseline and follow-up raw scores (and the log 
transformed raw scores) were transformed to z-scores using the means and standard deviations (SD) 
of the healthy control group at baseline as the reference group [10;16]. The z-score transformation 
ensured that higher scores indicated better performance for all tests. Composite domain z-scores 
were calculated as the mean of the z-scores for the tests included in each domain (except Verbal 
memory and Attention domain each consisting of only one test z-score). The standard deviation of 
composite scores will not necessarily be 1.00 after this transformation, and consequently baseline 
and follow-up composite domain z-scores were restandardized using the baseline composite domain 
z-score mean and SD of the control group to ensure that the control group had a restandardized 
baseline mean of 0.00 and a SD of 1.00. The within-subject change in performance in each 
cognitive domain over time was calculated by subtracting the restandardized baseline domain z-
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score from the corresponding restandardized domain z-score at follow-up to represent the 
development in cognitive functioning.  
If a subject missed only one of the test scores included in a domain, the domain mean was 
calculated from the remaining tests scores and was included in the analyses. If a subject missed 
more than one of the test scores included in a particular domain, the domain score was considered 
as missing. 
 
Statistical analyses 
Chi Square tests were used for comparisons of nominal data between independent groups. All 
cognitive data approximated a normal distribution and analysis was conducted in three steps: First, 
for each cognitive domain an overall repeated measures analysis of variance (ANOVA) was 
conducted with group (EOS, EOP or healthy controls) as between-subjects factor and time (baseline 
or follow-up) as within-subjects factor. Second, unadjusted and adjusted mean changes in the EOS 
group and the healthy control group were compared using independent samples t-tests and analysis 
of covariance (ANCOVA) with the baseline cognitive domain score as covariate. Third, unadjusted 
and adjusted mean changes in the EOS and EOP groups were compared using independent samples 
t-tests and ANCOVA with the baseline domain score, DUP score, and ratings of severity of 
negative and disorganization symptoms as covariates. The comparisons of the EOS group with the 
healthy controls and with the EOP group were conducted separately because different covariates 
were included. The baseline domain z-score was chosen as covariate, because preliminary analyses 
revealed significant and inverse correlations between baseline domain z-scores and change in the 
equivalent domain z-scores. Psychoticism symptom dimension severity was not included as a 
covariate because previous findings of no or minimal relationships to cognitive deficits in AOS 
[33;59]. Parental education/occupation and household income at baseline did not significantly 
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predict change in any cognitive domain z-score and were consequently not included as covariates in 
the statistical models. To avoid violation of the ANCOVA assumption of homogeneity of 
regressions slopes, two outlying results in the Speed of processing of EF domain were excluded 
from the analyses (outliers were defined as change scores > 2 SD above or < - 2 SD below the mean 
in the EOS and control group, respectively). Independent samples t-tests were used to compare the 
baseline and follow-up cognitive domain mean z-scores between the EOS and healthy control 
groups and between the EOS and EOP groups. Mann-Whitney tests were used to compare 
psychopathological data between the groups, while Wilcoxon tests were used to compare these data 
within the groups. Due to the small sample sizes and related increased risk for Type II errors, we 
did not correct for multiple comparisons to enable detection of relatively small effects (alpha was 
set at p < .05). 
Spearman’s rho was calculated in order to evaluate possible cross-sectional associations between 
symptom dimension severity ratings and cognitive domain scores at baseline and follow-up in the 
EOS group. Spearman’s rho was also calculated to assess possible associations between change in 
the cognitive domain score and the change in symptom dimension severity ratings (i.e. the symptom 
dimension rating at follow-up minus the corresponding rating at baseline) during the follow-up 
interval in this clinical group. Pearson correlation was calculated to assess possible associations 
between the changes in cognitive domain z-scores in EOS patients. Analyses were conducted using 
SPSS 11.0. 
 
Supplementary analyses 
Regarding co-morbid ICD-10 psychoactive substance abuse disorder (SUD), the adjusted 
comparisons of mean change in each cognitive domain score between EOS and controls were 
reanalysed after exclusion of EOS patients with co-morbid SUD at baseline or follow-up. Similarly, 
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the adjusted comparisons of mean change in each cognitive domain score between the EOS and 
EOP patient groups were reanalysed after exclusion of EOS and EOP patients with co-morbid SUD 
at baseline or follow-up. Results from these reanalyses are only reported in the Results section if 
they differed from the results obtained in the corresponding comparisons including the complete 
samples.  
 
Results 
Psychopathology and sociodemographics 
The baseline diagnosis of schizophrenia in the EOS group was confirmed in all cases at follow-up. 
In contrast, 91 % of baseline diagnoses in the EOP group were changed at the follow-up 
assessment, indicating a high prevalence of diagnostic instability in this group. Appendix A 
presents the follow-up diagnostic distributions of these subgroups. The absence of psychiatric 
diseases in the healthy controls was confirmed at follow-up.  
 
The current follow-up EOS patient group appears to be representative of the complete baseline EOS 
group, as no statically significant differences were found in baseline psychopathology, education, 
demographics, or cognition between the follow-up EOS patient group and the EOS patients not 
participating in the follow-up assessment. As shown in Table 1, the psychoticism and negative 
symptom dimension severity ratings improved significantly from baseline to follow-up in the EOS 
group, whereas no significant difference was observed regarding disorganisation symptom 
dimension severity ratings.  
 
Cognitive performance  
The repeated measures ANOVA indicated no significant interactions between group and time in 
any cognitive domain (see Figure 2). Thus, in this unadjusted perspective, one cannot reject the 
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possibility of a comparable change in each specific cognitive function in the three groups. A 
significant main effect of group was observed in all eight cognitive domains, and both patient 
groups generally performed worse than the healthy controls group. Finally, a significant main effect 
of time was found in all cognitive domains, except the Reaction time domain. Scores for all 
significant domains increased from baseline to follow-up, except the Verbal memory domain, which 
deteriorated significantly.  
Figure 2 here 
 
EOS patients versus healthy controls 
All baseline and follow-up mean cognitive domain z-scores were significantly lower in the EOS 
group than in the control group, except for the follow-up mean Reaction Time domain z-score (see 
Figure 2) (the p-values are not shown). The unadjusted comparisons of mean change over time did 
not show statistically significant differences between the two groups, but the confidence intervals of 
the unadjusted mean change in the Attention, Speed of processing of EF, and Set shifting domains 
indicate significant increase in the healthy controls, but not in the EOS group (see Table 2). 
Remarkably, a significant deterioration of the Verbal memory domain was found in the healthy 
controls.   
When comparisons of change scores were adjusted for baseline performance, analyses revealed a 
significant difference in the mean change in Attention and Set shifting domain z-score over time 
between EOS and controls (see Table 2). As shown in Table 2, the confidence intervals of the 
adjusted mean change in the Attention and Set shifting domains indicate significant change in the 
healthy controls, but not in the EOS group.  
Table 2 here 
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After exclusion of EOS patients with co-morbid ICD-10 SUD at any time point, reanalyses revealed 
a non-significant adjusted difference in mean change in the Attention domain z-score between the 
remaining EOS patients and the healthy controls (F(1,46) = 3.43, p = .071).  
 
EOS versus EOP patients 
Neither adjusted nor unadjusted comparisons revealed significant differences in mean change in any 
cognitive domain between the EOS and EOP groups (data not shown). None of the cross-sectional 
differences in any cognitive domain at baseline or follow-up between the EOS and EOP groups 
attained statistical significance (see Figure 2). 
 
Correlations between cognitive performance and psychopathology ratings in EOS patients  
At baseline, two significant and large cross-sectional correlations were observed between the 
Working memory z-score and psychoticism symptom dimension severity (N=9) (rho = .70, p = 
.035) and the negative symptom dimension severity (N=9) (rho = -.70, p = .036) in the EOS group. 
No other significant correlations were observed between any clinical symptom dimension ratings 
and cognitive domain z-scores at baseline.  
At follow-up, significant cross-sectional correlations were observed between the negative symptom 
dimension severity and Verbal memory (rho = -.49, p=.047), Attention (rho = -.56, p = .032), Speed 
of processing of EF (rho = -.71, p = .002), and Working Memory z-score (rho = -.58, p = .018). In 
addition, large significant cross-sectional correlations were found between the disorganization 
symptom dimension severity and Set Shifting (rho = -.54, p = .024) and Speed of processing of EF 
z-score (rho = -.66, p = .004) at follow-up. No other significant correlations were observed between 
any clinical symptom ratings and cognitive domain z-scores at follow-up.  
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Analyses of associations between the changes in cognitive domain z-scores in EOS patients 
revealed only two significant correlations, namely between change in Attention and change in 
Reaction time z-score (r = .59, p = .033) and between the latter and change Working memory z-
score (r = .82, p = .007).  
Analyses of associations between the changes in cognitive domain z-scores and the changes in 
symptom dimension severity ratings during the follow-up interval revealed large negative 
correlations between the change in Speed of processing of EF z-score and change in negative (rho = 
-.68, p = .004), psychoticism (rho = -.67, p = .004), and disorganization symptom dimension 
severity (rho = -.71, p = .002). Thus, reduced psychotic symptom severity was associated with 
improved Speed of processing of EF. None of the remaining correlations obtained statistical 
significance.  
 
Discussion 
At baseline, all eight specific cognitive domains were significantly impaired in EOS patients. In 
terms of the Reaction time, Motor speed, Speed of processing of EF, Planning, Working memory, 
and the Verbal memory domain, no significant difference in change in performance was observed 
between EOS patients and controls during the five-year follow-up interval. These results may 
suggest normal development in these specific cognitive functions that include components of 
attention and EF. Thus, it is possible that these specific cognitive deficits may be stable, trait-like 
aspects of EOS throughout this early illness phase. The adjusted comparison of change in attention 
and set shifting revealed a significantly larger increase in healthy controls than in EOS patients 
which was not observed in analyses unadjusted for baseline scores. The deficits in attention and set 
shifting at baseline resulted in substantial adjustment of the change score, but we suggest the results 
may reflect subnormal development in attention and set shifting in EOS patients during the first 5 
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years after full clinical presentation. After exclusion of patients with co-morbid ICD-10 SUD at 
baseline and follow-up, the adjusted between-group difference in attention change score lost 
statistical significance. However, the exclusion of a relatively large proportion of EOS patients 
decreased statistical power and the lack of significance may reflect a Type II error.  
 
The non-significant increase in Reaction time, Planning, and Working memory domains in the 
healthy controls suggest that these components of attention and EF may have approximated their 
mature functional level before or around the age at the baseline assessment. In contrast, the 
significant improvement with age in Attention, Set shifting, and Speed of processing of EF domains 
in the healthy controls may reflect functional progression throughout late adolescence and possibly 
in early adulthood. Developments in aspects of EF through these ages has previously been 
demonstrated in healthy subjects [19;37;73]. The improvement in set shifting observed in our 
controls is in accordance with previous findings [37;51;73;74] but earlier maturation has also been 
reported [17;19;83]. The significant improvement in attention observed in the healthy controls is 
also in accordance with earlier findings [2;24;53;79].  
We interpret the observed pattern of results as suggesting significant subnormal development in two 
of the three aspects of attention and EF with protracted maturational trajectories that overlap the age 
of onset of EOS. However, no significant developmental difference in the specific cognitive 
functions was found between EOS and EOP patients. Thus, the subnormal development in attention 
and set shifting may not be specific to EOS but could represent cognitive developmental deficits 
associated with psychotic disorders in general. The relative worsening of the set shifting and 
attention deficits in the EOS patients may reflect disruptive interactions among the EOS disease 
processes, or factors associated with the illness, and the neural networks mediating these functions. 
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However, they may also reflect the development of non-specific cognitive risk factors with 
protracted maturational trajectories.  
 
No differential deterioration was observed in the EOS patients through this illness phase, although 
possible deterioration of attention and set shifting cannot be ruled out. Thus, no clear cognitive 
indications of neurodegenerative processes in EOS patients were detected, and the observed 
subnormal maturational gains in components of attention and EF are in accordance with the 
neurodevelopmental model [58;82].  
 
Two previous studies examining the development of EF in EOS patients using WCST found 
stability, and lack of improvement, respectively, [16;64]. In terms of attention development in EOS 
patients, previous studies have observed either an abnormal lack of improvement [64] or 
deterioration in aspects of attention through late adolescence and early adulthood [24;62]. However, 
stability in attention deficits has also been reported over a relatively short follow-up period in EOS 
patients [16]. It is possible that the time frame for the longitudinal study by Cervellione and 
colleagues (2007) [16] may have been too short to detect possible developmental differences. Thus, 
the observed subnormal developments of attention and set shifting are in line with the EOS studies 
with longer follow-up intervals.  
Previous findings on the development of set shifting deficits in AOS patients are conflicting. Thus, 
longitudinal studies suggest stability [1;34], while other (cross-sectional) studies suggest 
deterioration [38;66;67]. Longitudinal studies suggest stability in attention in first-episode AOS 
patients [15;28]. These longitudinal results from AOS studies are in line with the hypothesis of 
particular developmental effects of the schizophrenia disease processes on cognitive components 
that have not completed their developmental trajectories around the time of illness onset. But they 
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are also in line with the hypothesis, that the attention and set shifting functions may represent 
cognitive risk factors.  
 
The observed lack of differential development between EOS and controls in planning and motor 
functioning are consistent with previous findings [24;64], although somewhat different aspects of 
motor function were assessed presently. The lack of significant differential development in verbal 
memory between EOS patients and healthy controls contrasts with previous findings [24]. However, 
we observed unexpected and significant deterioration of verbal memory in the healthy controls, and 
it is possible that tester-effects may explain this finding.  
 
Only few significant associations were found between cognition at baseline and follow-up and 
psychopathology at the same time point. We interpret these results as suggesting a large degree of 
independence between psychopathology and cognitive deficits in EOS both at illness onset and 
chronic phase. This is consistent with most previous studies [7;11;24;46;81], although not all [53]. 
The significant association between worse psychoticism dimension symptom severity and better 
working memory performance at baseline is in accordance with earlier findings of associations 
between more psychotic symptoms and better immediate visual recall [61] and more correct WCST 
responses [8] in AOS patients. However, this current association may be spurious and may reflect a 
Type I error. In terms of cognitive change, only the change in Speed of processing of EF was 
significantly associated with change in symptom severity in the EOS patients, which is in line 
previous studies of both EOS [16] and AOS patients [56]. In conclusion, we consider both the 
specific cognitive deficits and their development in our EOS sample to be essentially unaffected by 
the psychopathological symptoms.  
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The many insignificant correlations observed between the changes in the different cognitive 
domains over time may reflect low reliability of change scores, but may also indicate that the 
cognitive domains develop independently in EOS patients. In particular, no significant association 
was found between the changes in attention and set shifting, which may indicate independence 
between the developments of the two specific cognitive functions with subnormal maturational 
development in EOS patients. 
Due to the naturalistic design of the current study, possible confounding effects of antipsychotic 
medications on the specific cognitive functions could not be controlled. However, the enhancing 
influence of antipsychotic medications on cognitive functions may be minor, as the improvement in 
cognitive function associated with atypical [43;88] and typical antipsychotic treatment is relatively 
small [56]. Although not conclusive, no statistically significant differences in cognitive deficits 
have been found between EOS patients treated with antipsychotic medications from those untreated 
[81;85]. Thus, the observed subnormal development in attention and set shifting in EOS patients is 
unlikely to be related to antipsychotic medication effects.  
 
Methodological considerations 
We recognize that our patient sample sizes are small which increases the risk of Type II errors. In 
particular, the result of the adjusted comparison of change in the Speed of processing of EF 
performance between EOS patients and controls appears ambiguous (cf. Table 2). Due to the 
relatively low number of participants, factor analysis was not used to derive cognitive domains. The 
development in specific cognitive functions may be associated with baseline FSIQ and possible 
change in FSIQ during the follow-up interval. However, it was not possible to adjust the between-
group comparisons of change in specific cognitive functions for FSIQ. Given the diagnostic 
heterogeneity of the EOP group at follow-up, in particular, the onset of schizophrenia in some of the 
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patients, the interpretation of the comparisons of the development in specific cognitive functions in 
the EOS and EOP groups remains ambiguous. 
A very high diagnostic stability of EOS was found in the current study, but the follow-up diagnostic 
evaluation was not blind to the baseline diagnosis. Our finding is in accordance with the high 
degree of diagnostic stability of EOS observed in studies with diagnostic reassessments blind to 
initial diagnosis [32;35] and without (or probably without) blind reassessment [40;69;54;72] 
although lower estimates of diagnostic stability of EOS also have been reported [80]. The 
diagnostic stability of Other non-organic psychotic disorders (F28) in our EOP subgroup was very 
low. This estimate is in accordance with the relatively low estimates of stability for early-onset 
atypical psychosis [35] and early-onset psychosis not otherwise specified [23;40].  
 
We conclude that significant deficits were present in all specific cognitive domains at the time of 
the first episode in EOS patients. The post-psychotic development of most specific cognitive 
functions may be characterized as normal, indicating relatively stable cognitive deficits during this 
early illness phase. However, significant developmental delays in components of attention and EF 
were observed in EOS patients from the time of full clinical presentation to the chronic phase five 
years later, while results concerning the development of speed of processing of EF were ambiguous. 
The development of all specific cognitive functions, except the speed of processing of EF, was 
independent of the course of psychopathological symptom dimensions. The subnormal cognitive 
development in EOS patients was confined to the specific cognitive functions that were 
developmentally immature at the time of full clinical presentation. Further characterization of the 
developmental trajectories of the specific cognitive functions as well as their possible associations 
to functional outcome in EOS patients may eventually lead to invention of treatment strategies to 
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alleviate the subnormal development of immature specific cognitive functions and improve the 
relatively stable specific cognitive deficits in this early illness phase of EOS.   
Appendix A 
Baseline and follow-up diagnoses of the individual EOS and EOP patients 
Case Baseline diagnosis Follow-up diagnosis 
EOS patients 
1 Paranoid schizophrenia (F20.0) Residual schizophrenia 
(F20.50) 
2 Paranoid schizophrenia (F20.0) Paranoid schizophrenia 
(F20.00) 
3 Paranoid schizophrenia (F20.0) Paranoid schizophrenia 
(F20.00) 
4 Paranoid schizophrenia (F20.0) Paranoid schizophrenia 
(F20.04) 
5 Paranoid schizophrenia (F20.0) Paranoid schizophrenia 
(F20.04) 
6 Paranoid schizophrenia (F20.0) Residual Schizophrenia 
(F20.50) 
7 Paranoid schizophrenia (F20.0) Paranoid schizophrenia 
(F20.00) 
8 Paranoid schizophrenia (F20.0) Paranoid schizophrenia 
(F20.05) 
9 Paranoid schizophrenia (F20.0) Paranoid schizophrenia 
(F20.04) 
10 Paranoid schizophrenia (F20.0) Paranoid schizophrenia 
(F20.04) 
11 Paranoid schizophrenia (F20.0) Paranoid schizophrenia 
(F20.04) 
12 Paranoid schizophrenia (F20.0) Paranoid schizophrenia 
(F20.00) 
13 Hebephrenic schizophrenia 
(F20.1) 
Hebephrenic 
schizophrenia (F20.10) 
14 Hebephrenic schizophrenia 
(F20.1) 
Hebephrenic 
schizophrenia (F20.10) 
15 Undifferentiated schizophrenia 
(F20.3) 
Undifferentiated 
schizophrenia (F20.34) 
16 Undifferentiated schizophrenia 
(F20.3) 
Undifferentiated 
schizophrenia (F20.34) 
17 Schizophrenia, unspecified 
(F20.9) 
Schizophrenia, 
unspecified (F20.95) 
EOP patients 
1 Delusional disorder (F22.0) No psychiatric disorder 
(Z04)
1
 
2 Other acute predominantly 
delusional psychotic disorders 
Disturbance of activity 
and attention (F90.0) 
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(F23.3) 
3 Acute and transient psychotic 
disorder, unspecified (F23.9) 
Moderate depressive 
episode (F32.1) 
4 Other nonorganic psychotic 
disorders (F28) 
No psychiatric disorder 
(Z04)
1 
5 Other nonorganic psychotic 
disorders (F28) 
Paranoid schizophrenia 
(F20.04) 
6 Other nonorganic psychotic 
disorders (F28) 
Paranoid schizophrenia 
(F20.00) 
7 Other nonorganic psychotic 
disorders (F28) 
Paranoid schizophrenia 
(F20.05) 
8 Other nonorganic psychotic 
disorders (F28) 
Recurrent depressive 
disorder
2 
(F33.1) 
9 Other nonorganic psychotic 
disorders (F28) 
Panic disorder (F41.0) 
10 Other nonorganic psychotic 
disorders (F28) 
Other nonorganic psychotic 
disorders (F28) 
11 Other nonorganic psychotic 
disorders (F28) 
Delusional disorder 
(F22.0) 
1 
Examination and observation for other reasons 
2
 current episode moderate 
In terms of follow-up diagnoses in the EOS patient group, a positive predictive value of 100 % was 
observed, when including 2 EOS patients (12 %), who had complete remission at follow-up without 
antipsychotic treatment at that time point. Forty seven % had a continuous course and 41 % 
incomplete remission. In terms of the EOP patient group, the diagnostic stability of Other non-
organic psychotic disorders (F28) was very low (positive predictive value of 13 %). 
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Table 1 
 
Demographic and clinical characteristics for patients with EOS or EOP and controls  
 EOS (N = 
17) 
EOP (N = 
11)  
Controls (N 
= 38) 
p
1 
Mean age at baseline 
(SD) (years) 
15.6 (1.6) 15.2 (1.5) 15.6 (1.8) .941 / .489 
Mean age at follow-up 
(SD) (years) 
21.0 (1.5) 20.5 (1.5) 21.3 (1.9) .608 / .453 
Mean follow-up 
interval (SD) (years) 
5.4 (0.5) 5.4 (0.4) 5.6 (0.3) .117 / .927 
Gender (female/male) 8/9 6/5 22/16 .456 / .699 
Mean education at 
baseline
2 
(years) (SD) 
8.2 (1.8) 8.1 (1.4) 9.2 (1.9) .074 / .882 
Parental education/occupation
3
 
Academic/Bachelor 23.5 % 45.5 % 50.0 %  
Expert/Skilled 58.8 % 45.5 % 50.0 %  
Unskilled/Unemployed 17.6 % 9.1 % 0.0 %  .012 / .458 
Parental income (household)
3
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High income 35.3 % 36.4 % 81.6 %  
Middle income 41.2 % 36.4 % 13.2 %  
Low income 23.5 % 27.3 % 5.3 % .003 / .961 
Mean age at onset of psychotic 
symptoms (years) (SD) 12.8 (3.1) 12.6 (3.5)  / .872 
Mean DUP
4
 (years) 
(SD) 
2.43 (2.81) 2.33 (2.96)  / .906  
    p 
5
 
Mean psychoticism symptom dimension
6,9
 (SD)
 
Baseline 3.2 (1.3)  2.9 (0.7)   
Follow-up 2.0 (1.3) 1.2 (1.5) 
 
.021 / .012
 
Mean disorganization symptom dimension
7,9
 (SD) 
Baseline 1.5 (1.1) 1.2 (1.1)   
Follow-up 1.3 (1.1) 0.5 (0.9)  .449 / .140 
Mean negative symptom dimension
8,9
 (SD) 
Baseline 2.8 (0.9) 2.3 (0.8)   
Follow-up 2.0 (1.3) 1.8 (1.2)  .015 / .317 
Medication 
1
st
 gen. AP 
medications, BA
10
 (n) 
5 1   
2
nd
 gen. AP 
medications, BA
10
 (n) 
7 3   
1
st
 and 2
nd
 gen. AP 2    
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medications, BA
10
 (n)  
2 
1
st
 gen. AP 
medications, FU
11
 (n) 
2 0   
2
nd
 gen. AP 
medications, FU
11
 (n) 
4 2   
1
st
 and 2
nd
 gen. AP 
medications, FU
11
 (n) 
3 0   
1
 EOS group v. control group / EOS group v. EOP group 
2
 The number of years of school attendance; ranges: EOS (N=16): 4-10 years, EOP: 6-10 years, 
controls: 3-12 years  
3
 Frequency within patient and control groups at baseline 
4
 The duration (i.e. number of years) of untreated psychosis (DUP) 
5
 EOS baseline rating v. EOS follow-up rating / EOP baseline rating v. EOP follow-up rating 
6
 (∑ global rating of severity of hallucinations score; global rating of severity of delusions score)/2  
7
 (∑ global rating of severity of bizarre behaviour score; global rating of positive formal thought 
disorder score; inappropriate affect item rating score)/3  
8 (∑ global rating of affective flattening score; global rating of alogia score; global rating of 
avolition-apathy score; global rating of anhedonia-asociality score)/4  
9
 0 = None; 1 = Questionable; 2 = Mild; 3 = Moderate; 4 = Marked; 5 = Severe 
10
 Number of patients treated with first or second generation antipsychotic medications or both 
types at baseline 
11 
Number of patients treated with first or second generation antipsychotic medications or both types 
at follow-up 
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Table 2 Unadjusted and adjusted comparisons of mean change in cognitive domain z-scores 
between EOS patients and healthy controls 
 EOS (N=17) Healthy controls 
(N=38) 
p
1 
Domain (N)
2 
(N)
2
 p
3
 
Attention 
Mean change 
(SD) [CI]
4
 
(13) 1.02 (2.18) [-
0.17; 2.21] 
(38) 0.61 (0.87) 
[0.33; 0.89] 
.519 
Adjusted mean 
change (CI)
5
 
0.18 (-0.31; 0.67) 0.89 (0.62; 1.16) .017 
Reaction time 
Mean change 
(SD) [CI]
4
 
(15) 0.16 (1.45) [-
0.57; 0.89] 
(38) 0.17 (0.92) [-
0.12; 0.46] 
.988 
Adjusted mean 
change (CI)
5
 
-0.11 (-0.60; 
0.39) 
0.27 (-0.03; 0.58) .201 
Motor speed 
Mean change 
(SD) [CI]
4
 
(15) 0.65 (1.52) [-
0.12; 1.42] 
(38) 0.09 (1.12) [-
0.27; 0.45] 
.147 
Adjusted mean 
change (CI)
5
 
-0.01 (-0.52; 
0.49) 
0.35 (0.05; 0.65) .241 
Speed of processing of executive functions 
Mean change 
(SD) [CI]
4
 
(16) 0.50 (1.40) [-
0.19; 1.19] 
(38) 0.47 (1.08) 
[0.13; 0.81] 
.935 
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Adjusted mean 
change (CI)
5 
-0.13 (-0.75; 
0.48) 
(36) 0.61 (0.24; 
0.98) 
.065 
Set shifting 
Mean change 
(SD) [CI]
4
 
(16) 0.74 (1.82) [-
0.15; 1.63] 
(38) 0.77 (1.16) 
[0.40; 1.14] 
.945 
Adjusted mean 
change (CI)
5
 
0.16 (-0.34; 0.66) 1.02 (0.70; 1.34) .007 
Planning 
Mean change 
(SD) [CI]
4
 
(15) 0.50 (1.04) [-
0.03;1.03] 
(38) 0.22 (0.87) [-
0.06; 0.50] 
.317 
Adjusted mean 
change (CI)
5
 
0.22 (-0.23; 0.66) 0.33 (0.06; 0.61) .663 
Working memory 
Mean change 
(SD) [CI]
4
 
(9) 0.72 (0.93) 
[0.11; 1.33] 
(38) 0.05 (1.01) [-
0.27; 0.37] 
.075 
Adjusted mean 
change (CI)
5
 
0.27 (-0.45; 0.98) 0.16 (-0.15; 0.48) .800 
Verbal memory 
Mean change 
(SD) [CI]
4
 
(14) -0.91 (2.27) 
[-2.10; 0.28] 
(38) -0.98 (1.10) 
[-1.33; -0.63] 
.880 
Adjusted mean 
change (CI)
5
 
-1.18 (-2.06; -
0.30) 
 -0.89 (-1.39; -
0.38) 
.584 
1
 Independent-samples t-tests 
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2
 The number of EOS patients and healthy controls, respectively, with that particular domain score 
at both baseline and follow-up 
3
 Analyses of covariance; covariate was the corresponding baseline restandardized domain z-score 
(baseline domain z-score for Attention and Verbal memory) 
4
 95 % confidence interval of the unadjusted mean change 
5 
95 % confidence interval of the adjusted mean change 
 
 
 
Figure 1  
 
Retention of patients and healthy controls from baseline to follow-up assessment 
________________________________________________________________________________ 
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Figure 2 
Mean cognitive domain z-scores for EOS and EOP patient groups as well as for the control group at 
baseline and follow-up  
Excluded 
1 patient and 1 control withdrew consent 
during the assessment 
1 patient diagnosed with hydrocephalus 
revealed during the assessment 
2 patients with affective psychoses 
10 patients with schizotypal disorder 
1 patient was unable to participate in the 
cognitive assessment due to severe anxiety 
and psychotic symptoms 
 
Complete baseline 
33 patients and 45 controls with baseline 
cognitive data were eligible for follow-up   
 
Five-year follow-up recruitment 
Contact attempted for 33 patients and 45 
controls 
 
Follow-up 
Administration of 5-year follow-up protocol 
to 28 patients and 40 controls 
 
Complete follow-up  
17 patients with a baseline diagnosis of 
EOS, 11 patients with a baseline diagnosis 
of EOP, and 38 controls with baseline and 
follow-up cognitive assessment 
 
Baseline 
48 patients and 46 controls met the study’s 
inclusion criteria and none of the exclusion 
criteria 
Administration of baseline protocol 
 
Excluded 
5 patients and 5 controls were unable to 
contact or unwilling to consent  
 
Excluded 
2 controls with severe medical conditions 
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P
1
: P-value for repeated measures ANOVA main effect of group 
P
2
: P-value for repeated measures ANOVA main effect of time 
P
3
: P-value for repeated measures ANOVA time by group interaction 
Attention: Z-score log RVP A´  
Reaction time: Restandardized ((∑ z-score log RTI simple reaction time; z-score log RTI five-
choice reaction time)/2) 
Motor speed: Restandardized ((∑ z-score log RTI simple movement time; z-score log RTI five-
choice movement time)/2) 
Speed of processing of EF: Restandardized ((∑ z-score log Trail B-A; z-score Verbal Fluency 
(animal); z-score Figural Fluency)/3) 
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Set shifting: Restandardized ((∑ z-score log WCST perseverative errors (inclusive perseverative 
errors according to Nelson’s criteria); z-score log IED number of ED errors)/2) 
Planning: Restandardized ((∑ z-score SOC problems solved in minimum moves; z-score log SOC 
mean moves for five-move problems)/2) 
Working memory: Restandardized ((∑ z-score SSP; z-score log SWM strategy; z-score log SWM 
total Between errors; z-score log SWM total Within errors)/4)  
Verbal memory: Z-score log Buschke Total Recall 
 
